Results 71 to 80 of about 3,081 (193)

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, Volume 209, Issue 3, Page 1020-1030, September 2026.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

A single‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma

Cancer Medicine
Background MCD (MYD88L265P/CD79Bmut) diffuse large B‐cell lymphoma has a poor prognosis. There is no published clinical research conclusion regarding zanubrutinib or orelabrutinib for the initial treatment of MCD DLBCL.
Ting Deng, Shiyuan Zhang, Min Xiao, Jia Gu, Liang Huang, Xiaoxi Zhou   +5 more
doaj   +1 more source

NEW GENERATION BTK INHIBITORS AND RESISTANCE IN CLL TREATMENT

Hematology, Transfusion and Cell Therapy
Chronic lymphocytic leukemia (CLL) is an indolent lymphoproliferative malignancy characterized by monoclonal B lymphocytosis. BCR signaling plays a critical role in B cell development and survival.Bruton Tyrosine Kinase inhibitors (BTKi) disrupt the BCR ...
Aysun Gönderen
doaj   +1 more source

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

International audienceBrexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL in the US, and after ≥2 lines of prior therapy, including a BTKi in the EU.
Kersten, Marie José, Dreyling, Martin, Iacoboni, Gloria, Kanska, Justyna, Goy, Andre, Hill, Brian, T, Zheng, Dan, Patel, Krish, Herbaux, Charles, Forcade, Edouard, Damico Khalid, Rita, Mutsaers, Pim G.N.J., Reagan, Patrick, Hess, Georg, Martin Garcia-Sancho, Alejandro Martin, Shen, Rhine, Houot, Roch, Kloos, Ioana, Wang, Michael, Sanderson, Robin, Galal, Ahmed, van Meerten, Tom, Weng, Wen-Kai, Gine, Eva, Zhang, Wangshu, Topp, Max   +25 more
core   +1 more source

BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?

Haematologica
Not available.
Irene Dogliotti, Massimo Federico
openaire   +3 more sources

Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview

Background: Fixed-duration venetoclax plus rituximab (VR) is a standard therapy for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). However, evidence supporting its use after covalent BTK inhibitor (c-BTKi) therapy is scarce in clinical ...
Anastasia Kopsaftopoulou, Panayiotis Panayiotidis, Athanasios Liaskas, Aikaterini Bitsani, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos, Marina Siakantaris, Calliope Zerzi, Eleni Plata, Alexandros Machairas, Panagiotis Tsaftaridis, Fotios Panitsas, Rodanthi Fioretzaki, John V. Asimakopoulos, Maria Arapaki, Marina Belia, Alexia Piperidou, Aikaterini Benekou, Maria Dimou, Panagiota Petsa, Eliana Konstantinou   +20 more
core   +1 more source

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Introduction: Several randomized controlled trials have demonstrated superiority of BTK inhibitors (BTKis) over chemoimmunotherapy (CIT) in patients with treatment naïve (TN) CLL.
Collado, Rosa, Antic, Darko, Chiattone, Carlos, Tomasso, Annamaria, Herishanu, Yair, Doubek, Michael, Kislova, Maria, Salgado Sanchez, Rocio Nieves, Moia, Riccardo, Trentin, Livio, Davis, Zadie, Vitale, Candida, Arguello De Tomas, Miguel, Siakantaris, Marina, Tomic Vujovic, Kristina, Hatzimichael, Eleftheria, Rigolin, Gian Matteo, Rani, Lata, Angelopoulou, Maria, Koumpis, Andreas Epameinondas, Dimou, Maria, Machairas, Alexandros, Pavlova, Sarka, Vrachiolias, George, Serna, Angel, Sportoletti, Paolo, Chatzileontiadou, Sophia, Kotsianidis, Ioannis, Crespo, Marta, Coscia, Marta, Vassilakopoulos, Theodoros, Minga, Eva, Cellini, Alessandro, Michowitz, Maya Koren, Stamatopoulos, Kostas, Konstantinou, Eliana, Arrais-Rodrigues, Celso, Pospisilova, Sarka, Stavrogianni, Niki, Bosch Albareda, Francesc, Visentin, Andrea, Gaidano, Gianluca, Perobelli, Leila, Yildiz, Seyma, Rossi, Davide, Garcia-Serra, Rocio, Laurenti, Luca, Chatzikonstantinou, Thomas, Scarfo, Lydia, Puiggros, Anna, Rainer, Claus, Martini, Francesca, Chatzidimitriou, Anastasia, Silveira, Talita, Talimtzi, Persefoni, Papaioannou, Maria, Bradaschia, Marcello, Santucci, Rodrigo, Mouhssine, Samir, Gupta, Ritu, Jaksic, Ozren, Cuneo, Antonio, Efstathopoulou, Maria, Espinet, Blanca, Muntanola Prat, Ana, Konstantinou, Sevasti, Yagci, Munci, Gozzetti, Alessandro, Catherwood, Mark, Ramos, Sergio, Pangalis, Gerassimos, Ghia, Paolo, Romano, Ilaria, Chessa, Caterina, Murru, Roberta   +74 more
core   +1 more source

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

eJHaem
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj   +1 more source

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies

, 2021
The B-cell receptor signalling pathway plays a critical role in development of B-cell malignancies, and the central role of Bruton’s tyrosine kinase (BTK) activation in this pathway provides compelling rationale for BTK inhibition as a therapeutic ...
Chan Y Cheah, Katharine L Lewis
core   +1 more source

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

eLife
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph, Thomas E Wales, Sandrine Jayne, Robert G Britton, D Bruce Fulton, John R Engen, Martin JS Dyer, Amy H Andreotti   +7 more
doaj   +1 more source